Research Article

You have free access to this content

Search for Breast Cancer Biomarkers in Fractionated Serum Samples by Protein Profiling With SELDI-TOF MS

  1. Annemieke W.J. Opstal-van Winden1,2,
  2. Jos H. Beijnen2,3,
  3. Arnoud Loof4,
  4. Waander L. van Heerde4,
  5. Roel Vermeulen1,5,
  6. Petra H.M. Peeters1,6,
  7. Carla H. van Gils1,*

Article first published online: 24 JAN 2012

DOI: 10.1002/jcla.20492

Issue

Journal of Clinical Laboratory Analysis

Journal of Clinical Laboratory Analysis

Volume 26, Issue 1, pages 1–9, January 2012

Additional Information

How to Cite

Opstal-van Winden, A. W.J., Beijnen, J. H., Loof, A., van Heerde, W. L., Vermeulen, R., Peeters, P. H.M. and van Gils, C. H. (2012), Search for Breast Cancer Biomarkers in Fractionated Serum Samples by Protein Profiling With SELDI-TOF MS. J. Clin. Lab. Anal., 26: 1–9. doi: 10.1002/jcla.20492

Author Information

  1. 1

    Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

  2. 2

    Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands

  3. 3

    Beta Faculty, Department of Pharmaceutical Sciences, Division of Biomedical Analysis, Section of Drug Toxicology, Utrecht University, Utrecht, The Netherlands

  4. 4

    Central Laboratory for Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  5. 5

    Institute for Risk Assessment Sciences, Utrecht University, The Netherlands

  6. 6

    Department of Epidemiology, Public Health and Primary Care, Faculty of Medicine, Imperial College, London, United Kingdom

*Correspondence to: Carla H. van Gils, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Mail-drop Str 6.131, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.

Publication History

  1. Issue published online: 24 JAN 2012
  2. Article first published online: 24 JAN 2012
  3. Manuscript Accepted: 31 AUG 2011
  4. Manuscript Received: 20 JUL 2011

Funded by

  • University Medical Center Utrecht; Julius Center for Health Sciences and Primary Care

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (485K)

REFERENCES

  • 1
    Belluco C, Petricoin EF, Mammano E, et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 2007;14:2470–2476.
  • 2
    Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005;115:783–789.
  • 3
    Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.
  • 4
    van Winden AW, Gast MC, Beijnen JH, et al. Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: A case control study. BMC Med Genomics 2009;2:4.
  • 5
    Li J, Orlandi R, White CN, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005;51:2229–2235.
  • 6
    Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat 2006;96:83–90.
  • 7
    Song J, Patel M, Rosenzweig CN, et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 2006;52:1045–1053.
  • 8
    Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: The proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005;14:250–255.
  • 9
    Vlahou A, Laronga C, Wilson L, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203–209.
  • 10
    Engwegen JY, Helgason HH, Cats A, et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006;12:1536–1544.
  • 11
    Engwegen JY, Depla AC, Smits ME, et al. Detection of colorectal cancer by serum and tissue protein profiling: A prospective study in a population at risk. Biomark Insights 2008;3:375–385.
  • 12
    Engwegen JY, Mehra N, Haanen JB, Schellens JH, Voest EE, Beijnen JH. Identification of two new serum protein profiles for renal cell carcinoma. Oncol Rep 2009;22:401–408.
  • 13
    Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer: A review. Breast Cancer Res Treat 2009;116:17–29.
  • 14
    Hoffman SA, Joo WA, Echan LA, Speicher DW. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;849:43–52.
  • 15
    Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–867.
  • 16
    Faca V, Pitteri SJ, Newcomb L, et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007;6:3558–3565.
  • 17
    Vermeulen R, Lan Q, Zhang L, et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci USA 2005;102:17041–17046.
  • 18
    Restuccia U, Boschetti E, Fasoli E, et al. pI-based fractionation of serum proteomes versus anion exchange after enhancement of low-abundance proteins by means of peptide libraries. J Proteomics 2009;72:1061–1070.
  • 19
    Sahab ZJ, Iczkowski KA, Sang QX. Anion exchange fractionation of serum proteins versus albumin elimination. Anal Biochem 2007;368:24–32.
  • 20
    Yocum AK, Yu K, Oe T, Blair IA. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res 2005;4:1722–1731.
  • 21
    Karsan A, Eigl BJ, Flibotte S, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 2005;51:1525–1528.
  • 22
    Pelikan R, Bigbee WL, Malehorn D, Lyons-Weiler J, Hauskrecht M. Intersession reproducibility of mass spectrometry profiles and its effect on accuracy of multivariate classification models. Bioinformatics 2007;23:3065–3072.
  • 23
    Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: Some cautionary tales. Brief Funct Genomic Proteomic 2005;3:322–331.
  • 24
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289–300.
  • 25
    Timms JF, Arslan-Low E, Gentry-Maharaj A, et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 2007;53:645–656.
  • 26
    Trak-Smayra V, Dargere D, Noun R, et al. Serum proteomic profiling of obese patients: Correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825–832.
  • 27
    Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589–4596.
  • 28
    Sundsten T, Zethelius B, Berne C, Bergsten P. Plasma proteome changes in subjects with Type 2 diabetes mellitus with a low or high early insulin response. Clin Sci (Lond) 2008;114:499–507.
  • 29
    Woong-Shick A, Sung-Pil P, Su-Mi B, et al. Identification of hemoglobin-alpha and -beta subunits as potential serum biomar-kers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 2005;96:197–201.
  • 30
    Tammen H, Mohring T, Kellmann M, Pich A, Kreipe HH, Hess R. Mass spectrometric phenotyping of Val34Leu polymorphism of blood coagulation factor XIII by differential peptide display. Clin Chem 2004;50:545–551.
  • 31
    Jiang WG, Ablin R, Douglas-Jones A, Mansel RE. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep 2003;10:2039–2044.
  • 32
    Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271–284.
  • 33
    Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002;86:1440–1443.
  • 34
    Rollin D, Whistler T, Vernon SD. Laboratory methods to improve SELDI peak detection and quantitation. Proteome Sci 2007;5:9.
  • 35
    Harezlak J, Wang M, Christiani D, Lin X. Quantitative quality-assessment techniques to compare fractionation and depletion methods in SELDI-TOF mass spectrometry experiments. Bioin-formatics 2007;23:2441–2448.
  • 36
    Solassol J, Marin P, Demettre E, et al. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: Potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 2005;338:26–31.
  • 37
    Gast MC, van Gils CH, Wessels LF, et al. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin Chem Lab Med 2009;47:694–705.
View Full Article (HTML) Get PDF (485K)